These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20160479)

  • 1. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
    Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
    Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
    Ikeda M; Hayes CK; Schaller SJ; Longnecker R
    Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
    Cen O; Longnecker R
    Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
    Bieging KT; Amick AC; Longnecker R
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Pathways of p27
    Sora RP; Ikeda M; Longnecker R
    mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G; de Los Rios C; Zapata JM
    Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
    Allday MJ
    Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
    Bultema R; Longnecker R; Swanson-Mungerson M
    Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
    Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LCR of EBV makes Burkitt's lymphoma endemic.
    Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
    Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations.
    Anwar N; Kingma DW; Bloch AR; Mourad M; Raffeld M; Franklin J; Magrath I; el Bolkainy N; Jaffe ES
    Cancer; 1995 Oct; 76(7):1245-52. PubMed ID: 8630905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.
    D'Souza B; Rowe M; Walls D
    J Virol; 2000 Jul; 74(14):6652-8. PubMed ID: 10864681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
    Fish K; Chen J; Longnecker R
    Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBV latent membrane protein 2A orchestrates p27
    Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
    Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
    Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
    Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
    Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
    Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
    Komano J; Sugiura M; Takada K
    J Virol; 1998 Nov; 72(11):9150-6. PubMed ID: 9765461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.